|1.||Payá, Miguel: 2 articles (11/2006 - 04/2003)|
|2.||Alcaraz, Maria José: 1 article (11/2006)|
|3.||De Rosa, Salvatore: 1 article (04/2003)|
|4.||Alcaraz, M José: 1 article (04/2003)|
|5.||Terencio, M Carmen: 1 article (04/2003)|
|6.||Posadas, Inmaculada: 1 article (04/2003)|
04/01/2003 - "Cacospongionolide B suppresses the expression of inflammatory enzymes and tumour necrosis factor-alpha by inhibiting nuclear factor-kappa B activation."
01/01/1999 - "4. In the mouse air pouch injected with zymosan, cacospongionolide B administered into the pouch, induced a dose-dependent reduction in the levels of eicosanoids and tumour necrosis factor alpha (TNFalpha) in the exudates 4 h after the stimulus. "
01/01/1999 - "6 Cacospongionolide B is a new inhibitor of sPLA2 in vitro and in vivo, with anti-inflammatory properties in acute and chronic inflammation. "
11/01/2006 - "Cacospongionolide B and petrosaspongiolide M are representative examples of anti-inflammatory compounds in experimental models of acute or chronic inflammation. "
01/01/1999 - "5. The inflammatory response of adjuvant arthritis was reduced by cacospongionolide B, which did not significantly affect eicosanoid levels in serum, paw or stomach homogenates and did not induce toxic effects. "
01/01/1999 - "Cacospongionolide B, that is bioavailable when is given orally, reduced the elevated levels of sPLA2 present in paw homogenates of rats with adjuvant arthritis. "
|1.||NF-kappa B (NF-kB)
|4.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)